Karen Lin

Karen Lin

Auto-generated profile, based on publicly available information

Karen Lin

Natera, Inc., Austin, Texas

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
George AnsstasGeorge Ansstas
George Ansstas
KKKaram Khaddour
Karam Khaddour
SSSumedha Sudhaman
Sumedha Sudhaman
KLKaren Lin
Karen Lin
GBGriffin L. Budde
Griffin L. Budde
ATAlan Tan
Alan Tan
Purpose: Circulating tumor DNA (ctDNA) has emerged as an important biomarker for early recurrence detection and disease status monitoring during treatment in patients with cancer, including melanoma. We evaluate the prognostic value and impact of postoperative ctDNA detection in patients with stage I to IIIB melanoma using a clinically validated ctDNA assay. Experimental Design: We conducted a retrospective analysis of real-world data of patients with stage I to IIIB melanoma, including ctDNA results using a personalized, tumor-informed, 16-plex multiplex PCR–next-generation sequencing assay. Adjuvant treatment decisions and postsurgical plasma sample collection timepoints were at the physician’s discretion. ctDNA results were correlated with clinical outcomes. Results: Across 190 patients and a total of 1,578 samples, a median of 7 ctDNA tests (range: 1–33) per patient were performed over a median period of 24.6 months (range: 3.7–74.7). ctDNA positivity at any postoperative timepoint was significantly associated with shorter recurrence-free survival [RFS; hazard ratio (HR): 40.63; 95% confidence interval (CI), 19.9–82.96; P < 0.0001). This finding was also observed in patients specifically with regional or distant recurrence (HR: 39.55; 95% CI, 18.08–86.51; P < 0.0001). In multivariate analysis, ctDNA positivity was the most significant prognostic factor associated with RFS when compared with other clinicopathologic factors, including stage, sex, and mitotic rate (HR: 25.36; 95% CI, 9.16–70.3; P < 0.001). Conclusions: Our findings highlight the prognostic value of postsurgical, personalized ctDNA detection of recurrence and longitudinal disease surveillance in stage I to IIIB melanoma. The impact of ctDNA on real-world clinical decision-making highlights the need to assess outcomes when cancer management is influenced by ctDNA dynamics.

17 June 2026
Verified
Other
Open access
George AnsstasGeorge Ansstas
George Ansstas
KKKaram Khaddour
Karam Khaddour
SSSumedha Sudhaman
Sumedha Sudhaman
KLKaren Lin
Karen Lin
GBGriffin L. Budde
Griffin L. Budde
ATAlan Tan
Alan Tan
Representativeness of the study participants

17 June 2026
Verified
Other
Open access
George AnsstasGeorge Ansstas
George Ansstas
KKKaram Khaddour
Karam Khaddour
SSSumedha Sudhaman
Sumedha Sudhaman
KLKaren Lin
Karen Lin
GBGriffin L. Budde
Griffin L. Budde
ATAlan Tan
Alan Tan
Association between ctDNA and RFS. A, Kaplan–Meier estimates for RFS stratified by longitudinal ctDNA status. Patients who experienced anytime ctDNA positivity demonstrated shorter RFS compared with patients with serially negative ctDNA. B, Kaplan–Meier estimates for distant/regional RFS stratified by longitudinal ctDNA status. ctDNA positivity at any postoperative timepoint was associated with significantly inferior distant/regional RFS compared with patients with serially negative ctDNA. C, Kaplan–Meier estimates for RFS stratified by ctDNA status during post–definitive treatment surveillance. ctDNA positivity during post–definitive treatment surveillance was associated with inferior RFS when compared with patients who were serially ctDNA-negative. D, The unadjusted HRs (squares) and 95% CIs (horizontal lines) are shown for each prognostic factor. The vertical dotted line represents the null hypothesis. As shown, anytime ctDNA-positive was the most prognostic factor for RFS compared with all other factors. Adj Tx, adjuvant therapy, AIC, Akaike Information Criterion.

17 June 2026
Verified
Other
Open access
George AnsstasGeorge Ansstas
George Ansstas
KKKaram Khaddour
Karam Khaddour
SSSumedha Sudhaman
Sumedha Sudhaman
KLKaren Lin
Karen Lin
GBGriffin L. Budde
Griffin L. Budde
ATAlan Tan
Alan Tan
Recurrence-free survival stratified by ctDNA status within Stage II and Stage III melanoma. (A) Kaplan–Meier recurrence-free survival (RFS) curves for patients with Stage II melanoma, stratified by longitudinal ctDNA status. Patients who were ctDNA-positive at any postoperative timepoint experienced significantly inferior RFS compared with those who remained serially ctDNA-negative throughout follow-up (p < 0.0001). (B) Kaplan–Meier RFS curves for patients with Stage III melanoma, similarly demonstrating markedly shorter RFS among patients who were ctDNA-positive at any postoperative timepoint relative to those with persistently negative ctDNA results (p < 0.0001).

17 June 2026
Verified
Other
Open access
George AnsstasGeorge Ansstas
George Ansstas
KKKaram Khaddour
Karam Khaddour
SSSumedha Sudhaman
Sumedha Sudhaman
KLKaren Lin
Karen Lin
GBGriffin L. Budde
Griffin L. Budde
ATAlan Tan
Alan Tan
Overview plot of patients with stage IIA melanoma.

17 June 2026
Verified
Other
Open access
George AnsstasGeorge Ansstas
George Ansstas
KKKaram Khaddour
Karam Khaddour
SSSumedha Sudhaman
Sumedha Sudhaman
KLKaren Lin
Karen Lin
GBGriffin L. Budde
Griffin L. Budde
ATAlan Tan
Alan Tan
Overview plot of patients with stage IIB melanoma.